Regeneron shares should be bought on any pullbacks, says RBC Capital

RBC Capital expects Q3 sales of Regeneron's Eylea to be in-line with the consensus estimate, but the firm thinks that any pause in Eylea growth is temporary and will be more than offset by several fundamental drivers. The firm expects the company's top and bottom lines to grow 25%-30%, and it keeps an Outperform rating on the shares.

View Comments (0)